Johnson & Johnson banner

Johnson & Johnson
NYSE:JNJ

Watchlist Manager
Johnson & Johnson Logo
Johnson & Johnson
NYSE:JNJ
Watchlist
Price: 240.47 USD 1.13% Market Closed
Market Cap: $579.4B

Relative Value

The Relative Value of one JNJ stock under the Base Case scenario is hidden USD. Compared to the current market price of 240.47 USD, Johnson & Johnson is hidden .

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

JNJ Relative Value
HIDDEN
Show
Worst Case
Base Case
Best Case

Multiples Across Competitors

JNJ Competitors Multiples
Johnson & Johnson Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Johnson & Johnson
NYSE:JNJ
578.6B USD 6.1 21.6 15 18.4
US
Eli Lilly and Co
NYSE:LLY
997.2B USD 15.3 48.3 32.5 34.6
CH
Roche Holding AG
SIX:ROG
281.1B CHF 4.6 30 12.7 14.8
US
Merck & Co Inc
NYSE:MRK
303.5B USD 4.7 16.6 10.4 12.1
CH
Novartis AG
SIX:NOVN
230.9B CHF 5.3 21.2 13.1 16.8
UK
AstraZeneca PLC
LSE:AZN
216.1B GBP 5.2 32.1 15.3 22.4
IE
Endo International PLC
LSE:0Y5F
218B USD 94 -74.6 333.1 835.4
DK
Novo Nordisk A/S
CSE:NOVO B
1.3T DKK 4.2 12.7 9.3 11
US
Pfizer Inc
NYSE:PFE
154.7B USD 2.5 19.9 7.4 9.9
US
Bristol-Myers Squibb Co
NYSE:BMY
125.6B USD 2.6 20.8 7.3 9.6
UK
GlaxoSmithKline PLC
LSE:GSK
88.8B GBP 2.7 15.6 7.9 11.2
P/E Multiple
Earnings Growth PEG
US
Johnson & Johnson
NYSE:JNJ
Average P/E: 23.9
21.6
7%
3.1
US
Eli Lilly and Co
NYSE:LLY
48.3
28%
1.7
CH
Roche Holding AG
SIX:ROG
30
29%
1
US
Merck & Co Inc
NYSE:MRK
16.6
14%
1.2
CH
Novartis AG
SIX:NOVN
21.2
15%
1.4
UK
AstraZeneca PLC
LSE:AZN
32.1
38%
0.8
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -74.6 N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
12.7
7%
1.8
US
Pfizer Inc
NYSE:PFE
19.9
26%
0.8
US
Bristol-Myers Squibb Co
NYSE:BMY
20.8
N/A N/A
UK
GlaxoSmithKline PLC
LSE:GSK
15.6
18%
0.9
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
Johnson & Johnson
NYSE:JNJ
Average EV/EBITDA: 42.2
15
2%
7.5
US
Eli Lilly and Co
NYSE:LLY
32.5
18%
1.8
CH
Roche Holding AG
SIX:ROG
12.7
5%
2.5
US
Merck & Co Inc
NYSE:MRK
10.4
7%
1.5
CH
Novartis AG
SIX:NOVN
13.1
9%
1.5
UK
AstraZeneca PLC
LSE:AZN
15.3
10%
1.5
IE
E
Endo International PLC
LSE:0Y5F
333.1
N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
9.3
7%
1.3
US
Pfizer Inc
NYSE:PFE
7.4
-4%
N/A
US
Bristol-Myers Squibb Co
NYSE:BMY
7.3
-9%
N/A
UK
GlaxoSmithKline PLC
LSE:GSK
7.9
2%
3.9
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
Johnson & Johnson
NYSE:JNJ
Average EV/EBIT: 90.6
18.4
6%
3.1
US
Eli Lilly and Co
NYSE:LLY
34.6
17%
2
CH
Roche Holding AG
SIX:ROG
14.8
6%
2.5
US
Merck & Co Inc
NYSE:MRK
12.1
6%
2
CH
Novartis AG
SIX:NOVN
16.8
12%
1.4
UK
AstraZeneca PLC
LSE:AZN
22.4
23%
1
IE
E
Endo International PLC
LSE:0Y5F
835.4
N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
11
8%
1.4
US
Pfizer Inc
NYSE:PFE
9.9
-1%
N/A
US
Bristol-Myers Squibb Co
NYSE:BMY
9.6
10%
1
UK
GlaxoSmithKline PLC
LSE:GSK
11.2
12%
0.9